Every 8-K that STRATA SKIN SCIENCES INC (SSKN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SSKN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SSKN filings page.
Strata Skin Sciences, Inc. plans to delist its common stock from Nasdaq and terminate its SEC reporting obligations after failing to regain compliance with Nasdaq’s minimum $2.5 million stockholders’ equity requirement. Nasdaq has notified the company that trading is expected to be suspended at the opening on February 19, 2026.
The company anticipates filing a Form 25 around February 19, 2026 to deregister under Section 12(b), followed by a Form 15 around March 2, 2026 to begin “going dark” under Sections 12(g), 13(a) and 15(d). Management and the board cite expected time and cost savings, but acknowledge that delisting and going dark will likely make the stock more illiquid and harder for stockholders to sell.
Strata Skin Sciences, Inc. furnished a new investor presentation, dated December 2025, for investors and analysts. The company posted this presentation on its website and attached it as Exhibit 99.1 to a current report. The material is provided under a section that means it is being furnished, not filed, so it is not subject to certain liability provisions and will only be incorporated into other documents if specifically referenced.
STRATA Skin Sciences furnished an 8-K to announce it issued a press release with results for the third fiscal quarter ended September 31, 2025. The press release is included as Exhibit 99.1.
The disclosures under Item 2.02 and Item 7.01, including Exhibit 99.1, are being furnished, not filed, which means they are not subject to Section 18 liability and are not incorporated into other filings unless specifically referenced.
STRATA Skin Sciences updated its at-the-market equity program. The company filed a new prospectus supplement dated September 26, 2025 under its effective Form S-3 (File No. 333-283418), allowing registered “at-the-market” offerings of up to $11.0 million of common stock through Ladenburg Thalmann under an existing Equity Distribution Agreement.
The filing also includes a legal opinion from Stevens & Lee, P.C. as Exhibit 5.1 and related consent as Exhibit 23.1. This administrative step keeps the ATM facility current for potential future sales pursuant to the shelf registration.
Strata Skin Sciences reported it remains out of compliance with Nasdaq’s minimum $2,500,000 stockholders’ equity requirement. Nasdaq accepted the company’s plan and granted an extension until February 16, 2026 to regain compliance.
The company is evaluating actions discussed with Nasdaq. If compliance is not regained by the deadline, the common stock could become subject to delisting, though the company would be permitted to request a hearing, which would stay any suspension or delisting action during the process.
Strata Skin Sciences, Inc. reported that it has closed a previously announced registered direct offering of its common stock. The company issued and sold 1,097,547 shares of common stock at a purchase price of $2.204 per share, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. The transaction details were disclosed in a press release dated September 4, 2025, which is furnished as an exhibit and not deemed filed for liability purposes under the securities laws.
Strata Skin Sciences, Inc. filed an 8-K reporting a material event linked to a securities transaction. The filing lists exhibits that include a Placement Agency Agreement, a Securities Purchase Agreement (form), legal opinion and consent from Stevens & Lee, P.C., and a Pricing Press Release dated September 3, 2025. The form is signed by Dr. Dolev Rafaeli, President and CEO. These exhibits indicate the company has documented the legal and placement framework for a financing transaction and published pricing details on September 3, 2025.
The filing itself provides the existence of agreements and a pricing announcement but does not disclose offering size, price, net proceeds, or other financial terms within the text provided. The company's disclosures establish that placement counsel and transactional agreements are in place and that a public pricing announcement was released on the date shown.
Strata Skin Sciences, Inc. disclosed that on August 19, 2025 Nasdaq notified the company it is not in compliance with the Nasdaq Capital Market minimum stockholders' equity requirement of $2,500,000. The company's Quarterly Report for the quarter ended June 30, 2025 reported stockholders' equity below that threshold and the company does not meet alternative Nasdaq standards related to market value of listed securities or net income from continuing operations.
The Notice does not immediately affect the listing and the common stock continues trading under the symbol SSKN. Nasdaq gave Strata 45 calendar days, until October 3, 2025, to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days from the Notice date to evidence compliance. The company is evaluating options and plans to timely submit a plan, but stated there is no assurance the plan will be accepted or that compliance will be achieved.
STRATA Skin Sciences, Inc. furnished an investor presentation to the market by posting it on its website and attaching it as Exhibit 99.1 to a current report. The presentation is dated August 2025 and is intended to provide additional information to investors about the company.
The material in this investor presentation, and the related exhibit, is being furnished under a current report rather than filed, which means it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other securities filings unless specifically referenced.
Strata Skin Sciences, Inc. filed a current report to let investors know it has issued a press release covering its results of operations for the second fiscal quarter ended June 30, 2025. The company furnished the full text of this press release as Exhibit 99.1 to the report, using Items 2.02 and 7.01 to share the information. The company states that this exhibit is being furnished, not filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities filings unless specifically referenced.